Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Close this folderAnnex 1: Research proposal
View the documentI. Introduction
View the documentII. The Problem
View the documentIII. Research Question and Objectives of Proposed Study
View the documentIV. Study Approach
View the documentV. Anticipated Outcomes
View the documentVI. Methods
View the documentVII. Time Line and Resources
View the documentSelected References
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series
 

V. Anticipated Outcomes

1. The project will apply a systematic cross-national method for the assessment of pharmaceutical policy performance, using summative and formative evaluation techniques, through the standardized indicators and the political mapping technique.

2. The assessment of pharmaceutical policy performance will provide the basis for generating hypotheses to explain how different pharmaceutical policies, especially different public/private mixes, can affect the performance of the pharmaceutical sector.

3. The project will assist policy-makers responsible for pharmaceutical policy in identifying and substantiating specific strengths and weaknesses of existing policy, from national and cross-national perspectives, and in formulating strategies to improve the implementation of pharmaceutical policy.

4. The project will provide field testing of the standard indicators and the political mapping technique in a series of countries, and their potential development into a method of policy analysis and rapid assessment of pharmaceutical sector performance.

5. The project will facilitate the collection of data for the WHO's forthcoming World Drug Situation Report.

6. The project will identify specific policy innovations from cross-national learning that could improve the design and implementation of pharmaceutical policy within each country, and will propose ways to improve the political feasibility of implementing those innovations within a specific political context.

7. The project will enhance the capacity of Essential National Health Research within each country, through the development and application of the policy performance assessment methodology and the political mapping methodology, both of which can be applied to other areas of health policy.

8. The project will provide an impetus for international agencies to reconsider their own policies for the pharmaceutical sector, and will assist in strengthening the policy analysis capabilities of international agencies involved in supporting the development of national pharmaceutical policy.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014